메뉴 건너뛰기




Volumn 2, Issue 4, 2006, Pages 455-466

Atomoxetine: A novel treatment for child and adult ADHD

Author keywords

ADHD; Atomoxetine; Nonstimulants; Review

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ATOMOXETINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; HYDROXYZINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; QUINIDINE; SALBUTAMOL; SERTRALINE;

EID: 33847317497     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.455     Document Type: Article
Times cited : (36)

References (62)
  • 1
    • 16444366265 scopus 로고    scopus 로고
    • Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis
    • Adler LA, Spencer TJ, Milton DR, et al. 2005. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry, 66:294-9.
    • (2005) J Clin Psychiatry , vol.66 , pp. 294-299
    • Adler, L.A.1    Spencer, T.J.2    Milton, D.R.3
  • 2
    • 33645739829 scopus 로고    scopus 로고
    • Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
    • Allen AJ, Kurlan RM, Gilbert DL, et al. 2005. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65:1941-9.
    • (2005) Neurology , vol.65 , pp. 1941-1949
    • Allen, A.J.1    Kurlan, R.M.2    Gilbert, D.L.3
  • 3
    • 6344263841 scopus 로고    scopus 로고
    • Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder
    • Aman M. 2004. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol, 11:225-8.
    • (2004) Semin Pediatr Neurol , vol.11 , pp. 225-228
    • Aman, M.1
  • 4
    • 0004235298 scopus 로고    scopus 로고
    • [APA] American, Psychiatric Association. 4th ed, text revision (DSM-IV-TR). Washington DC: APA
    • [APA] American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision (DSM-IV-TR). Washington DC: APA.
    • (2000) Diagnostic and Statistical Manual of Mental Disorders
  • 5
    • 0029924275 scopus 로고    scopus 로고
    • The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder
    • Arnsten AF, Steere JC, Hunt RD. 1996. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry, 53:448-55.
    • (1996) Arch Gen Psychiatry , vol.53 , pp. 448-455
    • Arnsten, A.F.1    Steere, J.C.2    Hunt, R.D.3
  • 7
    • 0036838952 scopus 로고    scopus 로고
    • Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
    • Belle DJ, Ernest CS, Sauer JM, et al. 2002. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol, 42:1219-27.
    • (2002) J Clin Pharmacol , vol.42 , pp. 1219-1227
    • Belle, D.J.1    Ernest, C.S.2    Sauer, J.M.3
  • 8
    • 0036884937 scopus 로고    scopus 로고
    • Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder
    • [online]
    • Biederman J, Heiligenstein JH, Faries DE, et al. 2002. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/ hyperactivity disorder [online]. Pediatrics, 110:e75. URL: http://pediatrics.aappublications.org/.
    • (2002) Pediatrics , vol.110
    • Biederman, J.1    Heiligenstein, J.H.2    Faries, D.E.3
  • 9
    • 1942507310 scopus 로고    scopus 로고
    • Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports
    • Brown TE. 2004. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol, 14:129-36.
    • (2004) J Child Adolesc Psychopharmacol , vol.14 , pp. 129-136
    • Brown, T.E.1
  • 10
    • 3142706616 scopus 로고    scopus 로고
    • A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    • Buitelaar JK, Danckaerts M, Gillberg C, et al. 2004. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry, 13:249-57.
    • (2004) Eur Child Adolesc Psychiatry , vol.13 , pp. 249-257
    • Buitelaar, J.K.1    Danckaerts, M.2    Gillberg, C.3
  • 11
    • 0036848458 scopus 로고    scopus 로고
    • Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder
    • Bymaster FP, Karner JS, Nelson DL, et al. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology, 27:699-711.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 699-711
    • Bymaster, F.P.1    Karner, J.S.2    Nelson, D.L.3
  • 12
    • 0037374404 scopus 로고    scopus 로고
    • Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
    • Chalon SA, Desager JP, Desante KA, et al. 2003. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther, 73:178-91.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 178-191
    • Chalon, S.A.1    Desager, J.P.2    Desante, K.A.3
  • 13
    • 31544459553 scopus 로고    scopus 로고
    • The use of antidepressants to treat depression in children and adolescents
    • Cheung AH, Emslie GJ, Mayes TL. 2006. The use of antidepressants to treat depression in children and adolescents. CMAJ, 174:193-200.
    • (2006) CMAJ , vol.174 , pp. 193-200
    • Cheung, A.H.1    Emslie, G.J.2    Mayes, T.L.3
  • 14
    • 29544449443 scopus 로고    scopus 로고
    • Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
    • deLeon J, Armstrong SC, Cozza KL. 2006. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 47:75-85.
    • (2006) Psychosomatics , vol.47 , pp. 75-85
    • deLeon, J.1    Armstrong, S.C.2    Cozza, K.L.3
  • 15
    • 33847267772 scopus 로고    scopus 로고
    • Use of plasma concentration to guide atomoxetine doses in ADHD patients
    • 2005 May; Atlanta, GA, USA
    • Dunn DW, Turgay A, Weiss M, et al. 2005. Use of plasma concentration to guide atomoxetine doses in ADHD patients. American Psychiatry Association Annual Meeting. 2005 May; Atlanta, GA, USA. p 187.
    • (2005) American Psychiatry Association Annual Meeting , pp. 187
    • Dunn, D.W.1    Turgay, A.2    Weiss, M.3
  • 16
    • 33847279418 scopus 로고    scopus 로고
    • Package Insert, Strattera™
    • Eli Lilly and Company
    • Eli Lilly and Company. 2003. Package Insert, Strattera™.
    • (2003)
  • 17
    • 33745567446 scopus 로고    scopus 로고
    • Atomoxetine for weight reduction in obese women: A preliminary randomized controlled trial
    • [online]. Accessed April 15 2006
    • Gadde KM, Yonish GM, Wagner HR, et al. 2006. Atomoxetine for weight reduction in obese women: a preliminary randomized controlled trial [online]. Int J Obes. Accessed April 15 2006. URL: http://www.nature.com/ ijo/journal/vaop/ncurrent/abs/0803223a.html.
    • (2006) Int J Obes.
    • Gadde, K.M.1    Yonish, G.M.2    Wagner, H.R.3
  • 18
    • 30944446392 scopus 로고    scopus 로고
    • Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex
    • Gilbert DL, Ridel KR, Sallee FR, et al. 2006. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology, 31:442-9.
    • (2006) Neuropsychopharmacology , vol.31 , pp. 442-449
    • Gilbert, D.L.1    Ridel, K.R.2    Sallee, F.R.3
  • 19
    • 29944443819 scopus 로고    scopus 로고
    • Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders
    • Hah M, Chang K. 2005. Atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol, 15:996-1004.
    • (2005) J Child Adolesc Psychopharmacol , vol.15 , pp. 996-1004
    • Hah, M.1    Chang, K.2
  • 20
    • 0036644683 scopus 로고    scopus 로고
    • Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users
    • Heil SH, Holmes HW, Bickel WK, et al. 2002. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend, 67:149-56.
    • (2002) Drug Alcohol Depend , vol.67 , pp. 149-156
    • Heil, S.H.1    Holmes, H.W.2    Bickel, W.K.3
  • 21
    • 4644281608 scopus 로고    scopus 로고
    • Mania induction associated with atomoxetine
    • Henderson TA. 2004. Mania induction associated with atomoxetine. J Clin Psychopharmacol, 24:567-8.
    • (2004) J Clin Psychopharmacol , vol.24 , pp. 567-568
    • Henderson, T.A.1
  • 22
    • 12344311419 scopus 로고    scopus 로고
    • Aggression, mania, and hypomania induction associated with atomoxetine
    • Henderson TA, Hartman K. 2004. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics, 114:895-6.
    • (2004) Pediatrics , vol.114 , pp. 895-896
    • Henderson, T.A.1    Hartman, K.2
  • 23
    • 11444255970 scopus 로고    scopus 로고
    • Efficacy and safety of atomoxetine in childhood attention-deficit /hyperactivity disorder with comorbid oppositional defiant disorder
    • Kaplan S, Heiligenstein J, West S, et al. 2004. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord, 8:45-52.
    • (2004) J Atten Disord , vol.8 , pp. 45-52
    • Kaplan, S.1    Heiligenstein, J.2    West, S.3
  • 24
    • 0028933970 scopus 로고
    • Pharmacogenetics and Development: Are infants and children at increased risk for adverse outcomes?
    • Kearns, GL. 1995. Pharmacogenetics and Development: Are infants and children at increased risk for adverse outcomes? Curr Opinion Pediatr, 7:220-233.
    • (1995) Curr Opinion Pediatr , vol.7 , pp. 220-233
    • Kearns, G.L.1
  • 25
    • 4644226347 scopus 로고    scopus 로고
    • Once-daily atomoxetine treatment for children with attention-deficit /hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial
    • [online]
    • Kelsey DK, Sumner CR, Casat CD, et al. 2004. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial [online]. Pediatrics, 114:e1-8. URL: http://pediatrics.aappublications.org/.
    • (2004) Pediatrics , vol.114
    • Kelsey, D.K.1    Sumner, C.R.2    Casat, C.D.3
  • 26
    • 28444486103 scopus 로고    scopus 로고
    • Morning-versus evening-dosed atomoxetine: Effects of core ADHD symptoms
    • May; Atlanta, GA, USA
    • Kelsey DK, Sutton V, Lewis D, et al. Morning-versus evening-dosed atomoxetine: effects of core ADHD symptoms, American Psychiatry Association Annual Meeting. 2005 May; Atlanta, GA, USA. p 173.
    • (2005) American Psychiatry Association Annual Meeting , pp. 173
    • Kelsey, D.K.1    Sutton, V.2    Lewis, D.3
  • 27
    • 0034960305 scopus 로고    scopus 로고
    • An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder
    • Kratochvil CJ, Bohac D, Harrington M, et al. 2001. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 11:167-70.
    • (2001) J Child Adolesc Psychopharmacol , vol.11 , pp. 167-170
    • Kratochvil, C.J.1    Bohac, D.2    Harrington, M.3
  • 28
    • 0036633805 scopus 로고    scopus 로고
    • Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial
    • Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. 2002. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry, 41:776-84.
    • (2002) J Am Acad Child Adolesc Psychiatry , vol.41 , pp. 776-784
    • Kratochvil, C.J.1    Heiligenstein, J.H.2    Dittmann, R.3
  • 29
    • 23944461087 scopus 로고    scopus 로고
    • Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    • Kratochvil CJ, Newcorn JH, Arnold LE, et al. 2005. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry, 44:915-24.
    • (2005) J Am Acad Child Adolesc Psychiatry , vol.44 , pp. 915-924
    • Kratochvil, C.J.1    Newcorn, J.H.2    Arnold, L.E.3
  • 30
    • 19544392513 scopus 로고    scopus 로고
    • Atomoxetine use associated with onset of a motor tic
    • Ledbetter M. 2005. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol, 15:331-3.
    • (2005) J Child Adolesc Psychopharmacol , vol.15 , pp. 331-333
    • Ledbetter, M.1
  • 32
    • 12244298956 scopus 로고    scopus 로고
    • Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies
    • Michelson D, Adler L, Spencer T, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry, 53:112-20.
    • (2003) Biol Psychiatry , vol.53 , pp. 112-120
    • Michelson, D.1    Adler, L.2    Spencer, T.3
  • 33
    • 0036842531 scopus 로고    scopus 로고
    • Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study
    • Michelson D, Allen AJ, Busner J, et al. 2002. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry, 159:1896-901.
    • (2002) Am J Psychiatry , vol.159 , pp. 1896-1901
    • Michelson, D.1    Allen, A.J.2    Busner, J.3
  • 34
    • 3042559692 scopus 로고    scopus 로고
    • Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study
    • Michelson D, Buitelaar JK, Danckaerts M, et al. 2004. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 43:896-904.
    • (2004) J Am Acad Child Adolesc Psychiatry , vol.43 , pp. 896-904
    • Michelson, D.1    Buitelaar, J.K.2    Danckaerts, M.3
  • 35
    • 0035511622 scopus 로고    scopus 로고
    • Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study
    • [online]
    • Michelson D, Faries D, Wernicke J, et al. 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study [online]. Pediatrics, 108:e83. URL: http://pediatrics.aappublications.org/.
    • (2001) Pediatrics , vol.108
    • Michelson, D.1    Faries, D.2    Wernicke, J.3
  • 36
    • 14544286013 scopus 로고    scopus 로고
    • Atomoxetine treatment in children and adolescents with attention-deficit /hyperactivity disorder and comorbid oppositional defiant disorder
    • Newcorn JH, Spencer TJ, Biederman J, et al. 2005. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry, 44:240-8.
    • (2005) J Am Acad Child Adolesc Psychiatry , vol.44 , pp. 240-248
    • Newcorn, J.H.1    Spencer, T.J.2    Biederman, J.3
  • 38
    • 13244277705 scopus 로고    scopus 로고
    • A new paradigm for developing drugs in children: Atomoxetine as a model
    • Prasad S. 2005. A new paradigm for developing drugs in children: atomoxetine as a model. Arch Dis Child, 90(Suppl 1):13-16.
    • (2005) Arch Dis Child , vol.90 , Issue.SUPPL. 1
    • Prasad, S.1
  • 40
    • 13844276613 scopus 로고    scopus 로고
    • Attention-deficit/hyperactivity disorder: Cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine
    • Epub 2004 Nov 19
    • Sangal RB, Sangal JM. 2005. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine. Clin Neurophysiol, 116:640-7. Epub 2004 Nov 19. URL: http://www.elsevier.com.
    • (2005) Clin Neurophysiol , vol.116 , pp. 640-647
    • Sangal, R.B.1    Sangal, J.M.2
  • 41
    • 33847260253 scopus 로고    scopus 로고
    • The American Academy of Child and Adolescent Psychiatry (AACAP) Response to FDA's Public Health Advisory on Atomoxetine
    • [online]. Accessed 18 April 2006
    • Sarles R. 2005. The American Academy of Child and Adolescent Psychiatry (AACAP) Response to FDA's Public Health Advisory on Atomoxetine [online]. Accessed 18 April 2006. URL: http://www.aacap.org/ press_releases/index.htm.
    • (2005)
    • Sarles, R.1
  • 43
    • 1842532596 scopus 로고    scopus 로고
    • Seizures and prolonged QTc with atomoxetine overdose
    • Sawant S, Daviss SR. 2004. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry, 161:757.
    • (2004) Am J Psychiatry , vol.161 , pp. 757
    • Sawant, S.1    Daviss, S.R.2
  • 44
    • 10944237953 scopus 로고    scopus 로고
    • Attention deficit disorder and epilepsy
    • Schubert R. 2005. Attention deficit disorder and epilepsy. Pediatr Neurol, 32:1-10.
    • (2005) Pediatr Neurol , vol.32 , pp. 1-10
    • Schubert, R.1
  • 45
    • 0034786182 scopus 로고    scopus 로고
    • An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder
    • Spencer T, Biederman J, Heiligenstein J. 2001. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 11:251-65.
    • (2001) J Child Adolesc Psychopharmacol , vol.11 , pp. 251-265
    • Spencer, T.1    Biederman, J.2    Heiligenstein, J.3
  • 46
    • 0031977617 scopus 로고    scopus 로고
    • Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder
    • Spencer T, Biederman J, Wilens T, et al. 1998. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry, 155:693-5.
    • (1998) Am J Psychiatry , vol.155 , pp. 693-695
    • Spencer, T.1    Biederman, J.2    Wilens, T.3
  • 47
    • 0036928919 scopus 로고    scopus 로고
    • Overview and neurobiology of attention-deficit/hyperactivity disorder
    • Spencer TJ, Biederman J, Wilens TE, et al. 2002. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63(Suppl 12):3-9.
    • (2002) J Clin Psychiatry , vol.63 , Issue.SUPPL. 12 , pp. 3-9
    • Spencer, T.J.1    Biederman, J.2    Wilens, T.E.3
  • 48
    • 0036935774 scopus 로고    scopus 로고
    • Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
    • Spencer T, Heiligenstein JH, Biederman J, et al. 2002. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63:1140-7.
    • (2002) J Clin Psychiatry , vol.63 , pp. 1140-1147
    • Spencer, T.1    Heiligenstein, J.H.2    Biederman, J.3
  • 49
    • 18844395143 scopus 로고    scopus 로고
    • Atomoxetine ingestions in children: A report from poison centers
    • Spiller HA, Lintner CP, Winter ML. 2005. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother, 39:1045-8.
    • (2005) Ann Pharmacother , vol.39 , pp. 1045-1048
    • Spiller, H.A.1    Lintner, C.P.2    Winter, M.L.3
  • 50
    • 0004010456 scopus 로고    scopus 로고
    • 28th ed. Hagerstown, MD: Lippincott, Williams & Wilkins
    • Stedman's Medical Dictionary. 2005. 28th ed. Hagerstown, MD: Lippincott, Williams & Wilkins.
    • (2005) Stedman's Medical Dictionary
  • 51
    • 13744257053 scopus 로고    scopus 로고
    • Managing attention deficit/hyperactivity disorder: Unmet needs and future directions
    • Steer CR. 2005. Managing attention deficit/hyperactivity disorder: unmet needs and future directions. Arch Dis Child, 90(Suppl 1):i19-25.
    • (2005) Arch Dis Child , vol.90 , Issue.SUPPL. 1
    • Steer, C.R.1
  • 52
    • 0022289783 scopus 로고
    • A case of mania associated with tomoxetine
    • Steinberg S, Chouinard G. 1985. A case of mania associated with tomoxetine. Am J Psychiatry, 142:1517-8.
    • (1985) Am J Psychiatry , vol.142 , pp. 1517-1518
    • Steinberg, S.1    Chouinard, G.2
  • 53
  • 54
    • 4444267262 scopus 로고    scopus 로고
    • Atomoxetine and nonresponders to stimulants
    • Velcea G, Winsberg BG. 2004. Atomoxetine and nonresponders to stimulants. Am J Psychiatry, 161:1718-9.
    • (2004) Am J Psychiatry , vol.161 , pp. 1718-1719
    • Velcea, G.1    Winsberg, B.G.2
  • 55
    • 21044444747 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD
    • Weiss M, Tannock R, Kratochvil C, et al. 2005. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry, 44:647-55.
    • (2005) J Am Acad Child Adolesc Psychiatry , vol.44 , pp. 647-655
    • Weiss, M.1    Tannock, R.2    Kratochvil, C.3
  • 56
    • 0033429268 scopus 로고    scopus 로고
    • Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
    • Wennerholm A, Johansson I, Massele AY, et al. 1999. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9:707-14.
    • (1999) Pharmacogenetics , vol.9 , pp. 707-714
    • Wennerholm, A.1    Johansson, I.2    Massele, A.Y.3
  • 57
    • 9144256611 scopus 로고    scopus 로고
    • Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment
    • Wernicke JF, Adler L, Spencer T, et al. 2004. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol, 24:30-5.
    • (2004) J Clin Psychopharmacol , vol.24 , pp. 30-35
    • Wernicke, J.F.1    Adler, L.2    Spencer, T.3
  • 58
    • 0043124593 scopus 로고    scopus 로고
    • Cardiovascular effects of atomoxetine in children, adolescents, and adults
    • Wernicke JF, Faries D, Girod D, et al. 2003. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf, 26:729-40.
    • (2003) Drug Saf , vol.26 , pp. 729-740
    • Wernicke, J.F.1    Faries, D.2    Girod, D.3
  • 61
    • 0038556715 scopus 로고    scopus 로고
    • Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
    • Witcher JW, Long A, Smith B, et al. 2003. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 13:53-63.
    • (2003) J Child Adolesc Psychopharmacol , vol.13 , pp. 53-63
    • Witcher, J.W.1    Long, A.2    Smith, B.3
  • 62
    • 0021926971 scopus 로고
    • Clinical pharmacology of tomoxetine, a potential antidepressant
    • Zerbe RL, Rowe H, Enas CG, et al. 1985. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther, 232:139-43.
    • (1985) J Pharmacol Exp Ther , vol.232 , pp. 139-143
    • Zerbe, R.L.1    Rowe, H.2    Enas, C.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.